M6 PHARMACEUTICALS PLANS STREP THROAT VACCINE IND
Executive Summary
M6 PHARMACEUTICALS PLANS STREP THROAT VACCINE IND filing by the second half of 1995, the company said in a June 17 prospectus for an initial public offering. M6, a biotechnology firm "engaged in the research and development of vaccines, antibiotics and novel anti-infectives for the management of infectious diseases," hopes to raise $14.9 mil. from the offering of 2.3 mil. shares.